| FAMILY/DRUG NAME | MECHANISM | COMPANY | STATUS |
| Interferons - Mimic naturally-occurring, infection-fighting immune substance produced in the body | |||
| Intron A (Interferon alfa-2b | Immunomodulator | Merck, Whitehouse Station, NJ | FDA Approved 1991 |
| Pegasys (Peginterferon alfa-2a) | Immunomodulator | Genentech, South SanFrancisco, CA | FDA Approved 2005 |
| There are other brands of interferon approved for HCV treatment, but they have not been FDA-approved for HBV: Wellferon (Glaxo), Roferon(Hoffman-La Roche), and Infergen (Amgen) | |||
| Nucleoside Analogues - Interfere with the viral DNA polymerase enzyme used for hepatitis B virus reproduction | |||
| Epivir-HBV (Lamivudine) | Inhibits viral DNA polymerase | GlaxoSmithKline Philadelphia, PA | FDA Approved 1998 |
| Hepsera (Adefovir Dipivoxil) | Inhibits viral DNA polymerase | Gilead Foster City, CA | FDA Approved 2002 |
| Baraclude (Entecavir) | Inhibits viral DNA polymerase | Bristol-Myers SquibbPrinceton, NJ | FDA Approved 2005 |
| Tyzeka Sebivo (Europe) (Telbivudine) | Inhibits viral DNA polymerase | Novartis, Switzerland | FDA Approved 2006 |
| Viread (Tenofovir) | Inhibits viral DNA polymerase | Gilead Foster City, CA | FDA Approved 2008 |
| Clevudine (L-FMAU) | Inhibits viral DNA polymerase | Bukwang South Korea Eiasai, Japan | Approved S. Korea 2006 (Levovir) |
| Emtricitabine (FTC) | Inhibits viral DNA polymerase | Gilead Foster City, CA | Phase III |
| MIV-210 | Inhibits viral DNA polymerase | Medivir/Daewoong South Korea | Phase II |
| Amdoxovir (DAPD) | Inhibits viral DNA polymerase | RFS Pharm LLC Tucker, GA | Phase II |
| Non-Nucleoside Antivirals - Interfere with proteins involved in viral reproduction | |||
| NOV-205 (BAM 205) | Small Molecule | Novelos Newton, MA | Approved in Russia |
| LB80380 (ANA380) | Inhibits viral RNA polymerase | LG Life Sciences, S. Korea | Phase II |
| Myrcludex B | Entry Inhibition | Myr-GmbH, Germany | Phase IA, Germany |
| HAP Compound Bay 41-4109 | Inhibits viral nucleocapsid | AiCuris, Germany | Phase I |
| REP 9AC | HBsAg Release Inhibitor | REPLICor Inc. Montreal, Quebec | Phase I |
| Alinia (Nitazoxanide) | Small Molecule | Romark Labs Tampa, FL | Preclinical for HBV |
| Non-Interferon Immune Enhancers - Boost T-cell infection-fighting immune cells and natural interferon production | |||
| Zadaxin (Thymosin alpha-1) | Immune stimulator | SciClone San Mateo, CA | Orphan drug approval in US for liver cancer |
| CYT107 (Interleukin-7) | Immunemodulator | Cytheris, Paris, France | Phase I/IIa |
| DV-601 | HBV surface and core antigens | Dynavax, Berkeley, CA | Phase Ib |
| HBV Core Antigen Vaccine | Therapeutic HBV vaccine | Emergent Europe, U.K. | Phase I |
| Post-Exposure and/or Post-Liver Transplant Treatment | |||
| HyperHEP S/D | HBV Immuneglobulin | Talecris RTP, NC | FDA Approved 1977 |
| Nabi-HB | HBV Immuneglobulin | Biotest, Boca Raton, FL | FDA Approved 1999 |
| Hepa Gam B | HBV Immuneglobulin | CangeneCanada | FDA Approved 2006 |
Page last modified November 4, 2011
| 欢迎光临 肝胆相照论坛 (http://hbvhbv.info/forum/) | Powered by Discuz! X1.5 |